Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

oes not include the up-front payments in respect of in-licensed and acquired products made in Q1 2012.
  • Net debt at March 31, 2012 was $214 million (December 31, 2011: $468 million), a reduction of $254 million, principally due to the strong free cash flow generated in Q1 2012.

  • 2012 OUTLOOK


    Having made a strong start to the year, we reiterate our confidence in good earnings growth for 2012, while investing in our business to support sustained future growth.

    For the full year we now expect product sales growth in the mid teens range. Combining this with lower royalties and other revenues, which are expected to be 15% to 25% lower year on year, we are forecasting revenue growth in the low teens range.

    We anticipate the marginal dilution in gross margins seen this quarter will continue, reflecting the full year impact of our acquisition of ABH.

    We will continue to advance our promising pipeline of early and late stage programs, and we will be investing in our recent pipeline acquisitions and in the treatment of binge eating disorder, following recent positive data. The rate of increase in operating costs seen in the first quarter will not continue through the full year, but as we invest in our pipeline, continue to expand our international commercial activities and absorb a full year of ABH's operating costs, we now expect combined Non GAAP R&D and SG&A spending to increase by 12% to 14% compared to 2011.

    We expect our tax rate for 2012 to be in the range of 20% to 22%.

    FIRST QUARTER 2012 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS


    Products


    VPRIV manufacturing update

    • On February 22, 2012 Shire announced that the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use had approved the production of VPRIV in its new biologics manufacturing facility in Lexington, Massachusetts and this decision
      '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

    Related medicine technology :

    1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
    2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
    3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
    4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
    5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
    6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
    7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
    8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
    9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
    10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
    11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... CHICAGO , Aug. 27, 2015  Hill-Rom Holdings, ... to a management presentation at the Morgan Stanley Global ... ET. You are invited to listen to ... http://ir.hill-rom.com/events.cfm  or access it directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . ... be available one hour after the conclusion of the ...
    (Date:8/27/2015)... pharmaceutical and medical device companies and leading law firms will ... on Oct. 20, discussing issues surrounding regulatory compliance, ... Litigation Conferences has announced. To learn more ... The program is co-chaired by Megan Grossman ... Hart Yeary of Dechert LLP. Topics include: ...
    (Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
    Breaking Medicine Technology:Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
    ... 20, 2011 Comprehensive Care Corporation (OTC BB: CHCR), ... management services for managed care companies throughout the U.S., ... has been praised by the Chamber of Commerce of ... Leadership Advisory Council in "helping to shape and drive ...
    ... YDNT ) today announced record earnings per share for ... ended September 30, 2011. Sales for the third quarter ... $26.4 million reported for the third quarter of 2010. Income from ... $6.1 million in the prior year quarter. Net income for the ...
    Cached Medicine Technology:Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 3Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 4Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 5
    (Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
    (Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
    (Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
    (Date:8/27/2015)... ... 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon ... The new facility will be located at US Highway 19 North and Highlands Boulevard, less ... 18, and work on the project is slated to begin in September 2015. ...
    (Date:8/27/2015)... Collegedale, Tennessee (PRWEB) , ... August 27, 2015 , ... ... preservatives or high fructose corn syrup, is changing the expectation of how protein bars ... a rich, indulgent taste unlike any other protein bar on the market today. ...
    Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
    ... from having problems paying medical bills, and having bill problems ... medicines, a new study has found. According to a ... Journal of Public Health , after taking age, income and ... the odds of accruing debt related to medical care or ...
    ... Alan Mozes HealthDay Reporter , THURSDAY, June 16 ... habits of America,s teens, new data from the U.S. Centers ... Not only are high school kids guzzling far too ... CDC research team found. In fact, just one in ...
    ... pilot study of etanercept for treatment of dermatomyositis found ... the drug were successfully weaned from steroid therapy. These ... further investigate the safety and efficacy of etanercept. Results ... of Neurology , a journal published by Wiley-Blackwell on ...
    ... new study published today in the journal Child ... a poor "gut sense" of numbers can lead to ... math proficiency. This inaccurate number sense is just one ... led by Dr. Michele Mazzocco of the Kennedy Krieger ...
    ... UT Southwestern Medical Center scientists are shedding new ... fast-acting antidepressant response in patients with treatment-resistant depression. ... as a fast-acting antidepressant potentially has use in emergency ... very sharp increase that immediately relieves depression," said Dr. ...
    ... of death across a population has evolved in recent ... heart attack and cancer, the role of behavioral factorsincluding ... the 1990s. More recent research has begun to ... mortality. In the first comprehensive analysis of such studies, ...
    Cached Medicine News:Health News:Medical debt occurs despite insurance, UA study shows 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 3Health News:Etanercept shows promise for treating dermatomyositis 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2
    The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    Medicine Products: